Attralus, Inc., a South San Francisco, Calif.-based clinical stage biopharmaceutical company developing medicines to improve the lives of patients with systemic amyloidosis, closed a $116m Series B financing.
The round was led by Logos Capital with participation from Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital (a Citadel company), and Vivo Capital. Founding investor, venBio Partners, also participated in the financing.
Proceeds from the financing will be used to prepare the advancement of Attralus’ PAR therapeutics into clinical trials. The first PAR therapeutic, AT-03, is expected to begin a Phase 1 biodistribution study in systemic amyloidosis patients. Additionally, the company plans to advance the AT-01 clinical program, an amyloid-specific imaging radiotracer for the diagnosis of systemic amyloidosis. The funding will also enable Attralus to expand its team and infrastructure to support future growth.
Led by Mark Timney, Chief Executive Officer, Attralus is a clinical stage biopharmaceutical company advancing proprietary pan-amyloid removal (PAR) therapeutics designed to directly bind to and remove toxic amyloid in organs and tissues.
The company is advancing:
AT-01 Pan-Amyloid Diagnostic
AT-01 utilizes the company’s pan-amyloid peptide, an amyloid specific radiotracer to image all types of systemic amyloidosis through PET/CT imaging. In initial clinical trials, AT-01 has been shown to detect all types of amyloid deposits, including AL and ATTR, in major organs such as the heart, kidney, liver and spleen.
About AT-02 PAR Therapeutic
AT-02 is a full length IgG1 monoclonal antibody with the company’s pan-amyloid peptide attached to the Ig light chain enabling binding to all types of amyloid deposits. The Fc region of the antibody stimulates the immune system to remove amyloid deposits that are bound by AT-02.
About AT-03 PAR Therapeutic
AT-03 is a fusion of the company’s PAR-SAP (Serum Amyloid Protein) technology with a single-chain Fc. The PAR-SAP component mediates binding to all types of amyloid deposits, and the single-chain Fc stimulates the immune system to remove amyloid deposits that are bound by AT-03.
About AT-04 PAR Therapeutic
AT-04 is a fusion of the company’s pan-amyloid peptide with the Fc component of an IgG1 antibody. The PAR-peptide mediates binding to all types of amyloid deposits, and the Fc stimulates the immune system to remove amyloid deposits that are bound by AT-04.
In addition to strengthening its cash position with the Series B financing, Attralus has also strengthened its Board of Directors with the appointment of two new directors this quarter. In July 2021, the company announced the appointment of Jake Bauer, as an independent director. This one was followed by the appointment of Alexander Denner, Ph.D. who has joined the company’s Board of Directors.
FinSMEs
09/09/2021